Chadi is joined by Priya Sampathkumar, MD, infectious disease specialist and hospital epidemiologist, Mayo Clinic, to detail the COVID vaccine effort over the past 12 months and how the currently approved ones came to be safe and effective in such a short period of time. She then compares each vaccine in relation to their clinical trials and study populations, side effects (including some rare ones), and efficacy. Chadi and Dr. Sampathkumar converse on what it will take for herd immunity to be reached in the US, how worried we should be about the virus variants, proper precautions to be taken after vaccination, and so much more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
